Galapagos Announces ISABELA Ph III Study in Idiopathic Pulmonary Fibrosis

Galapagos Announces ISABELA Ph III Study in Idiopathic Pulmonary Fibrosis

Source: 
CP Wire
snippet: 
  • GLPG1690 has orphan drug status in US and Europe
  • Ph II results showed disease stabilization over 12 week period
  • ISABELA intended to support NDA and MAA in the US and EU